Alan Milinazzo is a partner in Heidrick & Struggles’ Boston office and a member of the Global Healthcare and Life Sciences Practice, specializing in the medical device sector.
Prior to joining Heidrick & Struggles, Alan was chief executive officer of InspireMD, a pioneer in embolic prevention systems (EPS) for coronary and vascular applications. He previously served as president and chief executive officer of Orthofix International N.V., a $600 million publicly traded global orthopedic and spine company, and as general manager of Medtronic, Inc.’s coronary and peripheral vascular businesses, where he was instrumental in the development and commercialization of several key products including the company’s first coronary drug-coated stent platform, Endeavor.
Alan also spent 12 years with Boston Scientific in multiple global sales and marketing leadership roles during a period of unprecedented top line growth in the cardiology franchise.
Alan currently serves as the executive chair of Opsens (TSX OPSS) and director and chair of the Compensation Committee of Flexion Therapeutics (Nasdaq: FLXN). Prior directorships include CasMed (Nasdaq CASM, acquired by Edwards Life Science), Nasdaq LDR Spine (Nasdaq LDRH acquired by Zimmer-Biomet), Medpace (acquired by PE sponsor Cinven), HET Systems (acquired by Covidien), LumenR (acquired by Boston Scientific), and The Musculoskeletal Transplant Foundation (MTF).Education:
Alan earned a bachelor degree, cum laude, from Boston College and interned at the White House, the US House of Representatives and the John F. Kennedy Library.